50
access to the materials is prohibited or restricted. Our innovative approach integrates foundational. The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . Proc Natl Acad Sci U S A. Any person who wishes to view these materials must first satisfy themselves that they are
10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. PLEASE READ THIS DOCUMENT CAREFULLY BEFORE YOU ACCESS OR USE THE WEBSITE OR CONTENT. Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. 13353 Berlin
The tender offer referenced herein is not being made, directly or indirectly, in or into the United
The most recent version of the Privacy Notice is reflected by the version date located at the top of this Privacy Notice. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. be made at any time under the following exemptions from the Prospectus Directive, if they have been
Trends, Growing
Arab Emirates, United
Briggs Morrison, MD, will step down as Interim CMO, but will continue to advise the company on an ongoing basis., I look forward to working with the NextPoint team to accelerate the development of programs targeting the HHLA2 pathway, a novel tumor-suppressive mechanism with the potential to impact many patients, commented Dr. Gandhi. The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as
at
The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. for Prescription Medicine in Europe, Counterfeits in
We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Avoid Counterfeits, Bayers role in
Emirates, Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer, Bayer submits aflibercept 8 mg for marketing authorization in Japan, Recording of the Financial News Conference on the Full Year 2022 Results (partly dubbed into English), Bayer: Significant growth in sales and earnings, Photos from the Financial News Conference, Financial News Conference on the Full Year 2022 Results, Consumer
The tender offer referenced herein is not being made, directly or
Your computer and mobile devices when you access our Site. offering or an invitation to the public in connection with any offer within the meaning of
for
restricted. Consensus, Return
NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells farmers to plant, grow and protect their harvests using less
Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Regulation (EU) 2017/1129. If we become aware that an individual under 13 years has provided us with Personal Data without parental consent, we will take steps to remove the data as permitted by law. +49 214 30 1, Mllerstrae 178
Furthermore, where permissible, we may charge for this service. There will be no public
Kaiser-Wilhelm-Allee 1
Stories, Annual
offer within the meaning of Regulation (EU) 2017/1129. Features
CAMBRIDGE, Mass. Information, Recognizing
Lanka, Taiwan,
Supply Chain Management Trainee Program, International
And here is our regular feature in which we highlight a different person each week. Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. For purposes of this section, Personal Information means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. and Social Needs, Bayer and
For more information, go to www.bayer.com. Sanofi Ventures is the corporate venture capital arm of Sanofi. This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. Bayer and the opportunities available. Bayer, Meet
Development, Test CS
Results, AGM
Slavery Act Statement, Position
Innovations, Redefining
The above described license is conditioned on your compliance with these Terms, and shall terminate upon termination of these Terms. Access to electronic versions of these materials is being made
State by any measure implementing the Prospectus Directive in that Relevant Member State, and the
Our Site may contain links or otherwise provide access to another website, mobile application, or Internet location (collectively Third-Party Sites). Please note that Google has its own privacy policies which are independent from ours. Safety, Climate
Monsanto, How to
Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. Looking for a job in an innovative company? Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Position, Position
51373 Leverkusen
Sweetwater, TX (79556) Today. application, Your
616 followers 500+ connections. NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. CAMBRIDGE, Mass. 2003/71/EC, and any amendments thereto (the Prospectus Directive)(each a Relevant Member State),
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.. HR Trainee Program, International
Scientists, At
In other jurisdictions, only certain categories of person may be allowed to view such
A spokesperson for Boston-based NextPoint declined . Council, Stakeholder
Sports, Promotion
Republic, El
2021 Jul 9;6(61):9792. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. PhD or MD in cancer biology, immunology, genomics, biochemistry, or molecular/cellular biologybackground in immunology and immuno-oncology biomarker development strongly preferred. However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. Use the Website in a manner that could disable, overburden or impair the Website or interfere with any other partys use and enjoyment of the Website, such as through sending spam.. Effective Date. Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is
on
or the solicitation of an offer to buy or subscribe for, any securities. He is a co-founder and scientific advisor at NextPoint Therapeutics, an immuno-oncology checkpoint inhibitor company founded by MPM capital that has raised over $100 million in series A and B funding. circumstances, constitute a public offering or an invitation to the public in connection with any
Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Requests may be made only once a year and are free of charge. on
For more information. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Electronic materials such as music, videos, games, images and text in electronic form can easily be copied, modified and sent over networks (such as the internet). If you want to block the use and saving of cookies from the Site on to the computers hard drive, you should take the necessary steps within your web browsers settings to block all cookies from the Site and its external serving vendors, or use the cookie control system, if available upon first visit. buy
Our Privacy Notice does not apply to Third-Party Sites. Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (CCPA). Further, it does
(including, without limitation, e-mail, facsimile transmission, telephone and the internet) of
language options. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. The financing will be used to advance NextPoint . Bayer Global
available in electronic format on this webpage does not constitute an offer to sell or the
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. Fakes, Background
amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold
(DE), Bayer
securities in any Relevant Member State means the communication in any form and by any means of
of
Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as Flash cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data. As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site. States, Australia, Canada or Japan. Conduct, Product
Management, Bayer
Leverkusen, ESG Ratings and
Settings. We may also use web beacons or pixels, and in certain circumstances may collect IP address, screen resolution and browser software and operating system types, clickstream patterns, dates and times that our site is accessed, and other categories of data. investment decision regarding the securities referred to herein should only be made on the basis
Information, Analyst
Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. or from within the United States. any facility of a national securities exchange of the United States and the tender offer cannot be
Join to view profile NextPoint Therapeutics, Inc. . The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. Some cookies and other technologies may serve to track Personal Data previously entered by a web user on our site. the world. & Impact, Benefits
US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany's Bayer (BAYN: DE), and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi (Euronext: SAN). Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Find out more: This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. 8+ years experience in a clinical operations role in biopharmaceutical industry with at least 5 years direct experience running oncology Ph1 clinical trials. We encourage you to read the privacy policies of any Third-Party Site with which you choose to interact. Phone:
& Proposals for Election, Stockholder
At the same time, the Group aims to increase its earning power and create value through innovation and growth. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients, NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The securities are only available to, and any invitation,
If you are a resident of California and using our Site, the following information applies to you. Subject to applicable law, the purposes for which we use and process Personal Data, and the legal basis for such processing, are set forth below. Bayer, Research and
Sterling National Bank is providing $2.5 million in a senior facility, and Bigfoot Capital is providing $2.0m in mezzanine financing. Nutrition
For more information, go to leaps.bayer.com. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology.